Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Outlook Therapeutics announced that the U.S. FDA has granted their appeal following the Formal Dispute Resolution process regarding their Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for treating neovascular age-related macular degeneration (nAMD). The FDA recognizes substantial evidence of effectiveness from clinical tri…